Non-VAEs in ≥5% of patients
| AE . | No. of patients experiencing AE (% all patients) . | No. of patients stopping nilotinib because of AE (% of all patients) . | |
|---|---|---|---|
| Any grade . | Grade 3-4 . | ||
| Rash | 30 (14) | 8 (4) | 4 (2) |
| Hepatitis | 17 (8) | 4 (2) | 7 (3) |
| Pancreatitis | 15 (7) | 5 (2) | 7 (3) |
| Systemic | 12 (5) | 2 (1) | 3 (1) |
| Other gastrointestinal (nausea, diarrhea) | 10 (5) | 0 (0) | 1 (<1) |
| AE . | No. of patients experiencing AE (% all patients) . | No. of patients stopping nilotinib because of AE (% of all patients) . | |
|---|---|---|---|
| Any grade . | Grade 3-4 . | ||
| Rash | 30 (14) | 8 (4) | 4 (2) |
| Hepatitis | 17 (8) | 4 (2) | 7 (3) |
| Pancreatitis | 15 (7) | 5 (2) | 7 (3) |
| Systemic | 12 (5) | 2 (1) | 3 (1) |
| Other gastrointestinal (nausea, diarrhea) | 10 (5) | 0 (0) | 1 (<1) |